Print

ChemoCentryx, Inc. (CCXI) to Report Data for CCX140, an Orally Administered CCR2 Inhibitor, at the American Society of Nephrology's Kidney Week 2012  
10/24/2012 8:33:40 AM

MOUNTAIN VIEW, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that preclinical data for CCX140, a novel, orally administered inhibitor of the chemokine receptor known as CCR2, will be presented at The American Society of Nephrology's (ASN) Kidney Week 2012, to be held in San Diego, California, October 30 – November 4. A poster entitled, "The CCR2 Chemokine Receptor Antagonist CCX140 Improves Renal Function in Diabetic Mice Expressing Human CCR2," is scheduled for presentation on Saturday, November 3, 2012, from 10:00 AM - 12:00 PM PT. The poster will highlight preclinical findings demonstrating robust and rapid improvements of albuminuria and hyperglycemia following administration of CCX140.